An updated review on drug-induced cholestasis: Mechanisms and investigation of physicochemical properties and pharmacokinetic parameters

Lee, 2003, Drug-induced hepatotoxicity, N Engl J Med, 349, 474, 10.1056/NEJMra021844 Benichou, 1990, Criteria of drug-induced liver disorders. Report of an international consensus meeting, J Hepatol, 11, 272, 10.1016/0168-8278(90)90124-A Bjornsson, 2005, Outcome and prognostic markers in severe drug-induced liver disease, Hepatology, 42, 481, 10.1002/hep.20800 Friis, 1992, Drug-induced hepatic injury: An analysis of 1100 cases reported to the Danish Committee on Adverse Drug Reactions between 1978 and 1987, J Intern Med, 232, 133, 10.1111/j.1365-2796.1992.tb00562.x Lewis, 2000, Drug-induced liver disease, Med Clin North Am, 84, 1275, 10.1016/S0025-7125(05)70287-X Padda, 2011, Drug-induced cholestasis, Hepatology, 53, 1377, 10.1002/hep.24229 Viteri, 1979, Erythromycin ethylsuccinate-induced cholestasis, Gastroenterology, 76, 1007, 10.1016/S0016-5085(79)91333-7 Moradpour, 1994, Chlorpromazine-induced vanishing bile duct syndrome leading to biliary cirrhosis, Hepatology, 20, 1437, 10.1002/hep.1840200610 Erlinger, 1997, Drug-induced cholestasis, J Hepatol, 26, 1, 10.1016/S0168-8278(97)82326-4 Geubel, 2003, Bile duct disorders, Clin Liver Dis, 7, 295, 10.1016/S1089-3261(03)00028-X Russell, 2003, The enzymes, regulation, and genetics of bile acid synthesis, Annu Rev Biochem, 72, 137, 10.1146/annurev.biochem.72.121801.161712 Norlin, 2007, Enzymes in the conversion of cholesterol into bile acids, Curr Mol Med, 7, 199, 10.2174/156652407780059168 Chiang, 2009, Bile acids: Regulation of synthesis, J Lipid Res, 50, 1955, 10.1194/jlr.R900010-JLR200 Hofmann, 1994, Bile Acids Reichen, 1976, Uptake of bile acids by perfused rat liver, Am J Physiol, 231, 734, 10.1152/ajplegacy.1976.231.3.734 Van Dyke, 1982, Bile acid transport in cultured rat hepatocytes, Am J Physiol, 243, G484 Kouzuki, 1998, Contribution of sodium taurocholate co-transporting polypeptide to the uptake of its possible substrates into rat hepatocytes, J Pharmacol Exp Ther, 286, 1043 Marion, 2011, Differential disposition of chenodeoxycholic acid versus taurocholic acid in response to acute troglitazone exposure in rat hepatocytes, Toxicol Sci, 120, 371, 10.1093/toxsci/kfr014 Agellon, 2000, Intracellular transport of bile acids, Biochim Biophys Acta, 1486, 198, 10.1016/S1388-1981(00)00057-3 El-Seaidy, 1997, Lack of evidence for vesicle trafficking of fluorescent bile salts in rat hepatocyte couplets, Am J Physiol, 272, G298 Pauli-Magnus, 2006, Hepatobiliary transporters and drug-induced cholestasis, Hepatology, 44, 778, 10.1002/hep.21359 Rost, 2001, Expression and localization of the multidrug resistance proteins MRP2 and MRP3 in human gallbladder epithelia, Gastroenterology, 121, 1203, 10.1053/gast.2001.28648 Ballatori, 2005, OSTalpha-OSTbeta: A major basolateral bile acid and steroid transporter in human intestinal, renal, and biliary epithelia, Hepatology, 42, 1270, 10.1002/hep.20961 Akita, 2002, Transport activity of human MRP3 expressed in Sf9 cells: Comparative studies with rat MRP3, Pharm Res, 19, 34, 10.1023/A:1013699130991 Rius, 2006, Substrate specificity of human ABCC4 (MRP4)-mediated cotransport of bile acids and reduced glutathione, Am J Physiol Gastrointest Liver Physiol, 290, G640, 10.1152/ajpgi.00354.2005 Ballatori, 2005, Biology of a novel organic solute and steroid transporter, OSTalpha-OSTbeta, Exp Biol Med (Maywood), 230, 689, 10.1177/153537020523001001 Ballatori, 2009, OST alpha-OST beta: A key membrane transporter of bile acids and conjugated steroids, Front Biosci, 14, 2829, 10.2741/3416 Akita, 2001, Sinusoidal efflux of taurocholate is enhanced in Mrp2-deficient rat liver, Pharm Res, 18, 1119, 10.1023/A:1010918825019 Trauner, 2005, Molecular regulation of hepatobiliary transport systems: Clinical implications for understanding and treating cholestasis, J Clin Gastroenterol, 39, S111, 10.1097/01.mcg.0000155551.37266.26 Zollner, 2007, Expression of bile acid synthesis and detoxification enzymes and the alternative bile acid efflux pump MRP4 in patients with primary biliary cirrhosis, Liver Int, 27, 920, 10.1111/j.1478-3231.2007.01506.x Teng, 2007, Hepatoprotective role of PXR activation and MRP3 in cholic acid-induced cholestasis, Br J Pharmacol, 151, 367, 10.1038/sj.bjp.0707235 Boyer, 2006, Upregulation of a basolateral FXR-dependent bile acid efflux transporter OSTalpha-OSTbeta in cholestasis in humans and rodents, Am J Physiol Gastrointest Liver Physiol, 290, G1124, 10.1152/ajpgi.00539.2005 Assem, 2004, Interactions between hepatic Mrp4 and Sult2a as revealed by the constitutive androstane receptor and Mrp4 knockout mice, J Biol Chem, 279, 22250, 10.1074/jbc.M314111200 Alnouti, 2009, Bile acid sulfation: A pathway of bile acid elimination and detoxification, Toxicol Sci, 108, 225, 10.1093/toxsci/kfn268 Hofmann, 1999, The continuing importance of bile acids in liver and intestinal disease, Arch Intern Med, 159, 2647, 10.1001/archinte.159.22.2647 Dietschy, 1968, Mechanisms for the intestinal absorption of bile acids, J Lipid Res, 9, 297, 10.1016/S0022-2275(20)43096-2 Shneider, 2001, Intestinal bile acid transport: Biology, physiology, and pathophysiology, J Pediatr Gastroenterol Nutr, 32, 407, 10.1097/00005176-200104000-00002 Hagenbuch, 2004, The sodium bile salt cotransport family SLC10, Pflugers Arch, 447, 566, 10.1007/s00424-003-1130-z Dawson, 2005, The heteromeric organic solute transporter alpha-beta, Ostalpha-Ostbeta, is an ileal basolateral bile acid transporter, J Biol Chem, 280, 6960, 10.1074/jbc.M412752200 Rao, 2008, The organic solute transporter alpha-beta, Ostalpha-Ostbeta, is essential for intestinal bile acid transport and homeostasis, Proc Natl Acad Sci USA, 105, 3891, 10.1073/pnas.0712328105 Trauner, 2003, Bile salt transporters: Molecular characterization, function, and regulation, Physiol Rev, 83, 633, 10.1152/physrev.00027.2002 Ming, 2010, Role of basolateral efflux transporter MRP4 in the intestinal absorption of the antiviral drug adefovir dipivoxil, Biochem Pharmacol, 79, 455, 10.1016/j.bcp.2009.08.029 Jonker, 2012, FXR and PXR: Potential therapeutic targets in cholestasis, J Steroid Biochem Mol Biol, 130, 147, 10.1016/j.jsbmb.2011.06.012 Claudel, 2005, The Farnesoid X receptor: A molecular link between bile acid and lipid and glucose metabolism, Arterioscler Thromb Vasc Biol, 25, 2020, 10.1161/01.ATV.0000178994.21828.a7 Perez, 2009, Bile-acid-induced cell injury and protection, World J Gastroenterol, 15, 1677, 10.3748/wjg.15.1677 Rodrigues, 1998, A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation, J Clin Invest, 101, 2790, 10.1172/JCI1325 Roberts, 1997, Cathepsin B contributes to bile salt-induced apoptosis of rat hepatocytes, Gastroenterology, 113, 1714, 10.1053/gast.1997.v113.pm9352877 Fickert, 2006, Lithocholic acid feeding induces segmental bile duct obstruction and destructive cholangitis in mice, Am J Pathol, 168, 410, 10.2353/ajpath.2006.050404 Salvioli, 1985, Bile acid binding in plasma: The importance of lipoproteins, FEBS Lett, 187, 272, 10.1016/0014-5793(85)81257-6 Davit-Spraul, 2009, Progressive familial intrahepatic cholestasis, Orphanet J Rare Dis, 4, 1, 10.1186/1750-1172-4-1 Dixon, 2009, Contribution of variant alleles of ABCB11 to susceptibility to intrahepatic cholestasis of pregnancy, Gut, 58, 537, 10.1136/gut.2008.159541 Kagawa, 2008, Phenotypic differences in PFIC2 and BRIC2 correlate with protein stability of mutant Bsep and impaired taurocholate secretion in MDCK II cells, Am J Physiol Gastrointest Liver Physiol, 294, G58, 10.1152/ajpgi.00367.2007 Lee, 2010, Sulindac and its metabolites inhibit multiple transport proteins in rat and human hepatocytes, J Pharmacol Exp Ther, 334, 410, 10.1124/jpet.110.165852 Fattinger, 2001, The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: A potential mechanism for hepatic adverse reactions, Clin Pharmacol Ther, 69, 223, 10.1067/mcp.2001.114667 Bohme, 1994, Cholestasis caused by inhibition of the adenosine triphosphate-dependent bile salt transport in rat liver, Gastroenterology, 107, 255, 10.1016/0016-5085(94)90084-1 Funk, 2001, Toxicology, 167, 83, 10.1016/S0300-483X(01)00460-7 Kis, 2009, Effect of membrane cholesterol on BSEP/Bsep activity: Species specificity studies for substrates and inhibitors, Drug Metab Dispos, 37, 1878, 10.1124/dmd.108.024778 Mano, 2007, Effects of bosentan, an endothelin receptor antagonist, on bile salt export pump and multidrug resistance-associated protein 2, Biopharm Drug Dispos, 28, 13, 10.1002/bdd.527 Morgan, 2010, Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development, Toxicol Sci, 118, 485, 10.1093/toxsci/kfq269 Dawson, 2012, In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans, Drug Metab Dispos, 40, 130, 10.1124/dmd.111.040758 Stieger, 2000, Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver, Gastroenterology, 118, 422, 10.1016/S0016-5085(00)70224-1 Fouassier, 2002, Contribution of mrp2 in alterations of canalicular bile formation by the endothelin antagonist bosentan, J Hepatol, 37, 184, 10.1016/S0168-8278(02)00107-1 van Erpecum, 2005, Biliary lipids, water and cholesterol gallstones, Biol Cell, 97, 815, 10.1042/BC20040088 Gonzales, 2009, Liver diseases related to MDR3 (ABCB4) gene deficiency, Front Biosci, 14, 4242, 10.2741/3526 Yoshikado, 2011, Itraconazole-induced cholestasis: Involvement of the inhibition of bile canalicular phospholipid translocator MDR3/ABCB4, Mol Pharmacol, 79, 241, 10.1124/mol.110.067256 Smith, 2000, MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping, J Biol Chem, 275, 23530, 10.1074/jbc.M909002199 Denk, 2004, Multidrug resistance-associated protein 4 is up-regulated in liver but down-regulated in kidney in obstructive cholestasis in the rat, J Hepatol, 40, 585, 10.1016/j.jhep.2003.12.001 Wang, 2011, ABC transporters, bile acids, and inflammatory stress in liver cancer, Curr Pharm Biotechnol, 12, 636, 10.2174/138920111795163986 Keitel, 2005, Expression and localization of hepatobiliary transport proteins in progressive familial intrahepatic cholestasis, Hepatology, 41, 1160, 10.1002/hep.20682 Chai, 2011, Changes of organic anion transporter MRP4 and related nuclear receptors in human obstructive cholestasis, J Gastrointest Surg, 15, 996, 10.1007/s11605-011-1473-2 Soroka, 2001, Cellular localization and up-regulation of multidrug resistance-associated protein 3 in hepatocytes and cholangiocytes during obstructive cholestasis in rat liver, Hepatology, 33, 783, 10.1053/jhep.2001.23501 Donner, 2001, Up-regulation of basolateral multidrug resistance protein 3 (Mrp3) in cholestatic rat liver, Hepatology, 34, 351, 10.1053/jhep.2001.26213 Yang, 2011, Interaction of troglitazone sulfate with hepatic basolateral and canalicular transport proteins, M1301 Köck, 2011, Inhibition of hepatic bile acid transporter MRP4: A potential risk factor for drug-induced liver injury (DILI), 495 Köck, 2012, Inhibition of the hepatic basolateral bile acid transporter MRP4 predicts cholestatic drug-induced liver injury (DILI) Leslie, 2007, Differential inhibition of rat and human Na+-dependent taurocholate cotransporting polypeptide (NTCP/SLC10A1)by bosentan: A mechanism for species differences in hepatotoxicity, J Pharmacol Exp Ther, 321, 1170, 10.1124/jpet.106.119073 Marion, 2007, Use of sandwich-cultured hepatocytes to evaluate impaired bile acid transport as a mechanism of drug-induced hepatotoxicity, Mol Pharm, 4, 911, 10.1021/mp0700357 Ansede, 2010, An in vitro assay to assess transporter-based cholestatic hepatotoxicity using sandwich-cultured rat hepatocytes, Drug Metab Dispos, 38, 276, 10.1124/dmd.109.028407 Kemp, 2005, Xenobiotics inhibit hepatic uptake and biliary excretion of taurocholate in rat hepatocytes, Toxicol Sci, 83, 207, 10.1093/toxsci/kfi020 Trottier, 2011, Profile of serum bile acids in noncholestatic volunteers: Gender-related differences in response to fenofibrate, Clin Pharmacol Ther, 90, 279, 10.1038/clpt.2011.124 Miyazaki, 1984, Effect of chenodeoxycholic and ursodeoxycholic acids on isolated adult human hepatocytes, Dig Dis Sci, 29, 1123, 10.1007/BF01317087 Jung, 2007, FXR agonists and FGF15 reduce fecal bile acid excretion in a mouse model of bile acid malabsorption, J Lipid Res, 48, 2693, 10.1194/jlr.M700351-JLR200 Hollands, 1998, Ileal exclusion for Byler's disease: An alternative surgical approach with promising early results for pruritus, J Pediatr Surg, 33, 220, 10.1016/S0022-3468(98)90435-3 Emond, 1995, Selective surgical management of progressive familial intrahepatic cholestasis (Byler's disease), J Pediatr Surg, 30, 1635, 10.1016/0022-3468(95)90440-9 Whitington, 1988, Partial external diversion of bile for the treatment of intractable pruritus associated with intrahepatic cholestasis, Gastroenterology, 95, 130, 10.1016/0016-5085(88)90301-0 Stedman, 2005, Nuclear receptors constitutive androstane receptor and pregnane X receptor ameliorate cholestatic liver injury, Proc Natl Acad Sci USA, 102, 2063, 10.1073/pnas.0409794102 Beilke, 2009, Constitutive androstane receptor-mediated changes in bile acid composition contributes to hepatoprotection from lithocholic acid-induced liver injury in mice, Drug Metab Dispos, 37, 1035, 10.1124/dmd.108.023317 Zollner, 2006, Role of nuclear receptors in the adaptive response to bile acids and cholestasis: Pathogenetic and therapeutic considerations, Mol Pharm, 3, 231, 10.1021/mp060010s Geier, 2007, Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration, Biochim Biophys Acta, 1773, 283, 10.1016/j.bbamcr.2006.04.014 Madhu, 1992, Effect of pregnenolone-16 alpha-carbonitrile and dexamethasone on acetaminophen-induced hepatotoxicity in mice, Toxicol Appl Pharmacol, 115, 191, 10.1016/0041-008X(92)90323-K Seo, 2000, Effects of benzothiazole on the xenobiotic metabolizing enzymes and metabolism of acetaminophen, J Appl Toxicol, 20, 427, 10.1002/1099-1263(200011/12)20:6<427::AID-JAT707>3.0.CO;2-# Stedman, 2006, Benefit of farnesoid X receptor inhibition in obstructive cholestasis, Proc Natl Acad Sci USA, 103, 11323, 10.1073/pnas.0604772103 Renga, 2011, Farnesoid X receptor suppresses constitutive androstane receptor activity at the multidrug resistance protein-4 promoter, Biochim Biophys Acta, 1809, 157, 10.1016/j.bbagrm.2011.01.008 Vore, 1997, Cholestatic properties and hepatic transport of steroid glucuronides, Drug Metab Rev, 29, 183, 10.3109/03602539709037580 Eurenius, 1969, The mechanism of glucocorticoid action on the phytohemagglutinin-stimulated lymphocyte. I. In vitro binding of corticosteroids to lymphoid tissue, Biochim Biophys Acta, 177, 572, 10.1016/0304-4165(69)90321-3 Crocenzi, 2003, Estradiol-17beta-d-glucuronide induces endocytic internalization of Bsep in rats, Am J Physiol Gastrointest Liver Physiol, 285, G449, 10.1152/ajpgi.00508.2002 Mottino, 2005, Role of microtubules in estradiol-17beta-D-glucuronide-induced alteration of canalicular Mrp2 localization and activity, Am J Physiol Gastrointest Liver Physiol, 288, G327, 10.1152/ajpgi.00227.2004 Mottino, 2002, Altered localization and activity of canalicular Mrp2 in estradiol-17beta-d-glucuronide-induced cholestasis, Hepatology, 35, 1409, 10.1053/jhep.2002.33327 Dawson, 1928, The phosphate ion and hydrolysis by pancreatic lipase, J Gen Physiol, 11, 357, 10.1085/jgp.11.4.357 Boaglio, 2010, Phosphoinositide 3-kinase/protein kinase B signaling pathway is involved in estradiol 17beta-d-glucuronide-induced cholestasis: Complementarity with classical protein kinase C, Hepatology, 52, 1465, 10.1002/hep.23846 Barosso, 2012, Sequential activation of classic PKC and estrogen receptor alpha is involved in estradiol 17ss-d-glucuronide-induced cholestasis, PLoS ONE, 7, e50711, 10.1371/journal.pone.0050711 Yamamoto, 2006, Estrogen receptor alpha mediates 17alpha-ethynylestradiol causing hepatotoxicity, J Biol Chem, 281, 16625, 10.1074/jbc.M602723200 Ruiz, 2012, Induction of hepatic multidrug resistance associated protein 3 by ethynylestradiol is independent of cholestasis and mediated by estrogen receptor, Drug Metab Dispos, 41, 275, 10.1124/dmd.112.047357 Trauner, 1999, Inflammation-induced cholestasis, J Gastroenterol Hepatol, 14, 946, 10.1046/j.1440-1746.1999.01982.x Moseley, 1997, Sepsis-associated cholestasis, Gastroenterology, 112, 302, 10.1016/S0016-5085(97)70250-6 Aoki, 2008, Effect of aminoguanidine on lipopolysaccharide-induced changes in rat liver transporters and transcription factors, Biol Pharm Bull, 31, 410, 10.1248/bpb.31.412 Aitken, 2006, Regulation of drug-metabolizing enzymes and transporters in inflammation, Annu Rev Pharmacol Toxicol, 46, 123, 10.1146/annurev.pharmtox.46.120604.141059 Zinchuk, 2005, Experimental LPS-induced cholestasis alters subcellular distribution and affects colocalization of Mrp2 and Bsep proteins: A quantitative colocalization study, Microsc Res Tech, 67, 65, 10.1002/jemt.20184 Kubitz, 1999, Regulation of the multidrug resistance protein 2 in the rat liver by lipopolysaccharide and dexamethasone, Gastroenterology, 116, 401, 10.1016/S0016-5085(99)70138-1 Denson, 2000, Interleukin-1beta suppresses retinoid transactivation of two hepatic transporter genes involved in bile formation, J Biol Chem, 275, 8835, 10.1074/jbc.275.12.8835 Ghose, 2004, Endotoxin leads to rapid subcellular re-localization of hepatic RXRalpha: A novel mechanism for reduced hepatic gene expression in inflammation, Nucl Recept, 2, 4, 10.1186/1478-1336-2-4 Trauner, 1998, Endotoxin downregulates rat hepatic ntcp gene expression via decreased activity of critical transcription factors, J Clin Invest, 101, 2092, 10.1172/JCI1680 Zollner, 2003, Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis, J Hepatol, 38, 717, 10.1016/S0168-8278(03)00096-5 Kojima, 2003, Changes in the expression and localization of hepatocellular transporters and radixin in primary biliary cirrhosis, J Hepatol, 39, 693, 10.1016/S0168-8278(03)00410-0 Congiu, 2009, Coordinate regulation of metabolic enzymes and transporters by nuclear transcription factors in human liver disease, J Gastroenterol Hepatol, 24, 1038, 10.1111/j.1440-1746.2009.05800.x Levy, 2003, Drug-induced cholestasis, Clin Liver Dis, 7, 311, 10.1016/S1089-3261(03)00032-1 Mohi-ud-din, 2004, Drug- and chemical-induced cholestasis, Clin Liver Dis, 8, 95, 10.1016/S1089-3261(03)00124-7 Chitturi, 2001, Drug-induced cholestasis, Semin Gastrointest Dis, 12, 113 Hamilton, 2008 Warner, 2012, Mitigating the inhibition of human bile salt export pump by drugs: Opportunities provided by physicochemical property modulation, in silico modeling, and structural modification, Drug Metab Dispos, 40, 2332, 10.1124/dmd.112.047068 Lecureur, 2000, Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein, Mol Pharmacol, 57, 24 Noe, 2001, Characterization of the mouse bile salt export pump overexpressed in the baculovirus system, Hepatology, 33, 1223, 10.1053/jhep.2001.24171 Byrne, 2002, The human bile salt export pump: Characterization of substrate specificity and identification of inhibitors, Gastroenterology, 123, 1649, 10.1053/gast.2002.36591 Wang, 2003, Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: Evidence for contingent unequal binding sites, Pharm Res, 20, 537, 10.1023/A:1023278211849 Hirano, 2006, High-speed screening and QSAR analysis of human ATP-binding cassette transporter ABCB11 (bile salt export pump) to predict drug-induced intrahepatic cholestasis, Mol Pharm, 3, 252, 10.1021/mp060004w Zhu, 2013, The use of pseudo-equilibrium constant affords improved QSAR models of human plasma protein binding, Pharm Res, 10.1007/s11095-013-1023-6 Benet, 2011, BDDCS applied to over 900 drugs, AAPS J, 13, 519, 10.1208/s12248-011-9290-9 Olah, 2007, WOMBAT and WOMBAT-PK: Bioactivity databases for lead and drug discovery., 760 van Staden, 2012, Membrane vesicle ABC transporter assays for drug safety assessment, Curr Protoc Toxicol, 10.1002/0471140856.tx2305s54 Modica, 2010, Deciphering the nuclear bile acid receptor FXR paradigm, Nucl Recept Signal, 8, e005, 10.1621/nrs.08005 Goodwin, 2002, Nuclear receptors. I. Nuclear receptors and bile acid homeostasis, Am J Physiol Gastrointest Liver Physiol, 282, G926, 10.1152/ajpgi.00044.2002 Saito, 2009, Technical pitfalls and improvements for high-speed screening and QSAR analysis to predict inhibitors of the human bile salt export pump (ABCB11/BSEP), AAPS J, 11, 581, 10.1208/s12248-009-9137-9 Ng, 2005, Quantitative structure–activity relationships of methotrexate and methotrexate analogues transported by the rat multispecific resistance-associated protein 2 (rMrp2), Eur J Pharm Sci, 26, 405, 10.1016/j.ejps.2005.07.008 Pedersen, 2008, Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2), J Med Chem, 51, 3275, 10.1021/jm7015683 Zhang, 2009, Support vector machine and pharmacophore-based prediction models of multidrug-resistance protein 2 (MRP2) inhibitors, Eur J Pharm Sci, 36, 451, 10.1016/j.ejps.2008.11.014 Sedykh, 2012, Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions, Pharm Res, 30, 996, 10.1007/s11095-012-0935-x Gonzalez, 2009, Inhibition requirements of the human apical sodium-dependent bile acid transporter (hASBT) using aminopiperidine conjugates of glutamyl-bile acids, Pharm Res, 26, 1665, 10.1007/s11095-009-9877-3 Zheng, 2009, Computational models for drug inhibition of the human apical sodium-dependent bile acid transporter, Mol Pharm, 6, 1591, 10.1021/mp900163d Zheng, 2010, Structural requirements of the ASBT by 3D-QSAR analysis using aminopyridine conjugates of chenodeoxycholic acid, Bioconjug Chem, 21, 2038, 10.1021/bc100273w Rais, 2010, Structural determinants for transport across the intestinal bile acid transporter using C-24 bile acid conjugates, Mol Pharm, 7, 2240, 10.1021/mp100233v Rais, 2010, Molecular switch controlling the binding of anionic bile acid conjugates to human apical sodium-dependent bile acid transporter, J Med Chem, 53, 4749, 10.1021/jm1003683 Greupink, 2012, In silico identification of potential cholestasis-inducing agents via modeling of Na(+)-dependent taurocholate cotransporting polypeptide substrate specificity, Toxicol Sci, 129, 35, 10.1093/toxsci/kfs188 Karlgren, 2012, Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): Influence of protein expression on drug-drug interactions, J Med Chem, 55, 4740, 10.1021/jm300212s Karlgren, 2012, In vitro and in silico strategies to identify OATP1B1 inhibitors and predict clinical drug-drug interactions, Pharm Res, 29, 411, 10.1007/s11095-011-0564-9 Akanuma, 2011, Molecular-weight-dependent, anionic-substrate-preferential transport of beta-lactam antibiotics via multidrug resistance-associated protein 4, Drug Metab Pharmacokinet, 26, 602, 10.2133/dmpk.DMPK-11-RG-063 Giacomini, 2010, Membrane transporters in drug development, Nat Rev Drug Discov, 9, 215, 10.1038/nrd3028 Ekins, 2009, Challenges predicting ligand-receptor interactions of promiscuous proteins: The nuclear receptor PXR, PLoS Comput Biol, 5, e1000594, 10.1371/journal.pcbi.1000594 Kortagere, 2012, Ligand- and structure-based pregnane X receptor models, Methods Mol Biol, 929, 359, 10.1007/978-1-62703-050-2_15 Khandelwal, 2008, Machine learning methods and docking for predicting human pregnane X receptor activation, Chem Res Toxicol, 21, 1457, 10.1021/tx800102e Kortagere, 2009, Hybrid scoring and classification approaches to predict human pregnane X receptor activators, Pharm Res, 26, 1001, 10.1007/s11095-008-9809-7 Honorio, 2007, 3D QSAR comparative molecular field analysis on nonsteroidal farnesoid X receptor activators, J Mol Graph Model, 25, 921, 10.1016/j.jmgm.2006.09.003 Zhang, 2007, 3D-QSAR studies with the aid of molecular docking for a series of non-steroidal FXR agonists, Bioorg Med Chem Lett, 17, 2156, 10.1016/j.bmcl.2007.01.079 Matter, 2012, Development of in silico filters to predict activation of the pregnane X receptor (PXR) by structurally diverse drug-like molecules, Bioorg Med Chem, 20, 5352, 10.1016/j.bmc.2012.04.020 Ung, 2007, In silico prediction of pregnane X receptor activators by machine learning approaches, Mol Pharmacol, 71, 158, 10.1124/mol.106.027623 Dybdahl, 2012, QSAR model for human pregnane X receptor (PXR) binding: Screening of environmental chemicals and correlations with genotoxicity, endocrine disruption and teratogenicity, Toxicol Appl Pharmacol, 262, 301, 10.1016/j.taap.2012.05.008 Honorio, 2005, Hologram quantitative structure–activity relationships for a series of farnesoid X receptor activators, Bioorg Med Chem Lett, 15, 3119, 10.1016/j.bmcl.2005.04.017 Genet, 2010, Structure–activity relationship study of betulinic acid, a novel and selective TGR5 agonist, and its synthetic derivatives: Potential impact in diabetes, J Med Chem, 53, 178, 10.1021/jm900872z Schuster, 2011, Pharmacophore-based discovery of FXR agonists. Part I: Model development and experimental validation, Bioorg Med Chem, 19, 7168, 10.1016/j.bmc.2011.09.056 Grienke, 2011, Pharmacophore-based discovery of FXR-agonists. Part II: Identification of bioactive triterpenes from Ganoderma lucidum, Bioorg Med Chem, 19, 6779, 10.1016/j.bmc.2011.09.039 Diaz Ochoa, 2012, A multi-scale modeling framework for individualized, spatiotemporal prediction of drug effects and toxicological risk, Front Pharmacol, 3, 204 Howell, 2012, In vitro to in vivo extrapolation and species response comparisons for drug-induced liver injury (DILI) using DILIsym: A mechanistic, mathematical model of DILI, J Pharmacokinet Pharmacodyn, 39, 527, 10.1007/s10928-012-9266-0